No Data
Zhejiang Huahai Pharmaceutical Gets China Nod for Type 2 Diabetes Drug
Zhejiang Huahai Pharmaceutical (600521.SH): Metformin and Ertugliflozin Tablets (I) have obtained the Pharmaceutical registration certificate.
On December 10, Guolonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced it has recently received the "Drug Registration Certificate" for Metformin and Empagliflozin Tablets (I) issued by the National Medical Products Administration. The approved product is intended to be used in conjunction with dietary control and exercise for adult patients with type 2 diabetes who are undergoing treatment with Empagliflozin and Metformin hydrochloride, aimed at improving blood sugar control in these patients.
Huahai Pharmaceutical Gets Nod to Register Dapagliflozin Tablets
Is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Latest Stock Performance A Reflection Of Its Financial Health?
Research reports digging for gold丨China Merchants: Zhejiang Huahai Pharmaceutical's Q3 profitability has significantly improved, maintaining a "strongly recommended" rating.
China Merchants research reports pointed out that Zhejiang Huahai Pharmaceutical (600521.SH) Q3 overall performance approaching the upper limit of the forecast, with a significant improvement in profitability. It is expected that the company's active pharmaceutical ingredient and formulation product structure will continue to adjust, the proportion of new products will increase, and the demonstration of lean management, economies of scale, and the effectiveness of technological transformation will drive a significant improvement in profit margin. Since the beginning of this year, several of the company's products have entered key clinical stages. Zhejiang Huahai Pharmaceutical is a leading domestic integrated enterprise in active pharmaceutical ingredients and formulations, with the turning point of active pharmaceutical ingredients and generic drug formulations trending upwards, profitability is expected to continue to rise, innovative drugs are gradually entering the harvesting period, and innovative assets
Zhejiang Huahai Pharmaceutical Gets China Nod for Anti-Tumor Injection
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
No Data
